Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
about
"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer ImmunotherapyPrimary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 SignalingRegulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.The docking protein p130Cas regulates cell sensitivity to proteasome inhibition.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsGene expression profiling predicts the development of oral cancer.Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.Targeting NF-κB in mouse models of lung adenocarcinoma.The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoBortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.Killer Immunoglobulin-like Receptors (KIR) haplogroups A and B track with Natural Killer Cells and Cytokine Profile in Aged Subjects: Observations from Octo/Nonagenarians in the Belfast Elderly Longitudinal Free-living Aging STudy (BELFAST).Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications.Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.Guggulsterone and Its Role in Chronic Diseases.Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHNRhesus macaque KIR bind human MHC class I with broad specificity and recognize HLA-C more effectively than HLA-A and HLA-BPolymorphisms of killer immunoglobulin-like receptors (KIRs) and HLA ligands in northeastern Thais.Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor.Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases
P2860
Q28081338-8BE89F52-7BA6-44EA-9E92-52806D2A9B16Q28481417-675632CD-8825-4B45-9E0E-4466C2BA5CF6Q28552654-7DE8E091-C5F5-4B60-A760-FEEA0D81073BQ33556178-30E5B68E-13A5-4922-B1CD-AADE4E2C949CQ34060635-A8DA38C2-D66E-47CD-98C4-93DBD936BB84Q34194704-38ED7491-A6BF-4338-B255-79808D783B06Q34218976-1EC4B2D2-0F2A-4F00-B101-DFC06F5B72ABQ34782013-77FE3B27-FFA1-4D11-8F8B-26446CC5DB0EQ36012652-F79F8F9A-4934-463A-AEB6-42ECE09F9A5FQ36478306-A804665C-E6D7-45EE-AA95-F119AAB4FB23Q36691438-E37FA99F-9232-49A6-A9C9-F66DE6FC1439Q36947423-99743E22-4362-4705-A641-34202989B5AAQ37280039-E48EDB51-EF90-4A75-B846-306B3F042B55Q37308200-4247DA95-82E2-4EE0-994E-86454C78A7A1Q37788246-B9FDF6B0-5516-43E0-910F-9193B99CEC4FQ37869903-3A5F56F0-A2BF-4CC5-8BD0-5A1292677F1AQ37876089-6D53CA01-DC5A-42FD-B376-77E744A05AF1Q38986185-5181033D-B0D3-48E1-A981-E1648C30EAE3Q38988598-F0786953-4DD2-4F10-A03D-1C98B686A701Q39425835-A181095D-F746-43EB-8534-44020C6F0ABFQ42355050-72C8A47A-4056-4BE5-AC19-750023EFAFC4Q42582499-1CB447B2-B61C-4906-9C4D-B93343FE63F1Q43896693-23966B08-1F98-41A6-9242-9FB5D8D1803EQ55642764-FCCDC3A5-1F64-4293-9F41-9BA679082251Q57922384-8149A08B-6570-4571-81F1-1DE84D6DA542
P2860
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Bortezomib up-regulates activa ...... ous cell carcinoma cell death.
@en
Bortezomib up-regulates activa ...... ous cell carcinoma cell death.
@nl
type
label
Bortezomib up-regulates activa ...... ous cell carcinoma cell death.
@en
Bortezomib up-regulates activa ...... ous cell carcinoma cell death.
@nl
prefLabel
Bortezomib up-regulates activa ...... ous cell carcinoma cell death.
@en
Bortezomib up-regulates activa ...... ous cell carcinoma cell death.
@nl
P2093
P2860
P1476
Bortezomib up-regulates activa ...... ous cell carcinoma cell death.
@en
P2093
Changyou Li
Daniel E Johnson
David S K Man
Rebecca J Leeman-Neill
P2860
P304
P356
10.1158/1535-7163.MCT-09-0327
P577
2009-07-28T00:00:00Z